Skip to content

Clinical Efficacy of Extracorporeal Shock Wave Therapy on Patellar Tendon Combined with Center of Coordination Point in the Fascial Manipulation for Patellar Tendinitis: A Randomized Controlled Trial

Clinical Efficacy of Extracorporeal Shock Wave Therapy on Patellar Tendon Combined with Center of Coordination Point in the Fascial Manipulation for Patellar Tendinitis: A Randomized Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600118509
Enrollment
Unknown
Registered
2026-02-06
Start date
2026-02-24
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patellar tendinitis

Interventions

experimental group:extracorporeal shock wave therapy on patellar tendon combined with center of coordination point in the fascial manipulation
control group:shockwave therapy only on patellar tendon

Sponsors

Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. Adults aged between 18 and 45 yearsWillingness to sign an informed consent form and ability to cooperate with the treatment and follow-up aspects of this study. 2. Meeting the diagnostic criteria for patellar tendinitis as outlined in "Practical Sports Medicine" (2023 edition); 3. Knee joint pain with a VAS score of >=3 and <=7; 4. No other orthopedic or neurological conditions that could affect lower limb strength or mobility; 5. Willingness to sign an informed consent form and ability to cooperate with the treatment and follow-up aspects of this study.

Exclusion criteria

Exclusion criteria: 1. History of knee joint surgery within the past year; 2. Presence of knee pain due to other causes, or conditions that affect the knee joint or impact its function (including but not limited to: transient synovitis, bone tuberculosis, bone tumors, acute traumatic arthritis, suppurative arthritis, rheumatoid arthritis, metabolic bone diseases, psoriatic arthritis, gouty arthritis, bone necrosis, ankylosing spondylitis, or active infections); 3. Presence of chronic knee pain caused by other reasons (such as post-herpetic neuralgia, osteoporosis, etc.); 4. Contraindications for shockwave therapy, such as deep venous thrombosis in the lower extremities, bleeding disorders or coagulation dysfunction, pregnancy, cognitive dysfunction, etc. 5. Presence of cancerous tumors, severe bronchiectasis, acute suppurative inflammation, high fever, active pulmonary tuberculosis, heart failure, severe anemia, cerebrovascular diseases, or the presence of a cardiac pacemaker implanted in the body; 6. Inability to participate in the trial due to other health issues, such as sudden severe trauma, sudden severe infectious diseases, etc.

Design outcomes

Primary

MeasureTime frame
the change in pain intensity;

Secondary

MeasureTime frame
the changes in the Lysholm knee scoring scale ;The changes in pain intensity ;the change in the thickness;

Countries

China

Contacts

Public ContactKe Songjian

Sun Yat-sen Memorial Hospital, Sun Yat-sen University

songjian112626@163.com+86 20 81332513

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 14, 2026